For years, the quest to treat acute myeloid leukemia (AML) has centered on a biological “don’t eat me” signal. Researchers identified CD47, a protein on the surface of cancer cells that tricks macrophages—the immune system’s scavenger cells—into ignoring the malignancy. By blocking this signal, scientists hoped to unlock the immune system’s natural ability to clear leukemia cells from the bone marrow.
However, clinical results have often fallen short of expectations, suggesting that AML cells possess more than one way to evade detection. New research indicates that the battle for immune clearance is more complex than a single protein switch. A critical immune checkpoint in AML has emerged in the form of sialylated CD43, a molecule that provides a secondary, potent shield against macrophage phagocytosis.
This discovery suggests that targeting CD47 alone may be insufficient given that CD43 acts as a redundant safety mechanism for the cancer. When CD47 is blocked, sialylated CD43 can still prevent macrophages from engulfing the leukemia cells, effectively maintaining the cancer’s invisibility cloak. By understanding how these two pathways interact, researchers are now identifying new leukemia targets to boost macrophage phagocytosis and improve patient outcomes.
The implications are significant for the development of combination therapies. If the immune system is being held back by multiple “brakes,” removing only one may not be enough to trigger a robust response. Targeting both CD47 and the sialylated version of CD43 could potentially synchronize the immune attack, forcing the body to recognize and destroy AML cells that were previously untouchable.
The Mechanics of Immune Evasion in AML
To understand why CD43 is critical, one must first understand the role of the macrophage. In a healthy system, macrophages identify abnormal or dying cells and consume them through a process called phagocytosis. In AML, the cancer cells hijack this process by overexpressing proteins that inhibit the macrophage’s appetite.
CD47 has long been the primary suspect. It binds to the SIRPα receptor on macrophages, sending a strong inhibitory signal that stops the macrophage from eating the cell. But the discovery of the role of CD43 adds a layer of biochemical complexity. CD43 is a heavily glycosylated protein, meaning it is covered in sugar chains. When these chains are “sialylated”—meaning they carry sialic acid—they interact with Siglec receptors on the immune cells.
These Siglec-sialic acid interactions function similarly to the CD47-SIRPα axis. They send a “stop” signal to the macrophage. When both CD47 and sialylated CD43 are present, the AML cell is essentially double-locked against immune clearance. This redundancy explains why some patients do not respond to CD47-blocking therapies; their cancer cells simply rely on the CD43 pathway to survive.
Comparing the Two Primary Checkpoints
| Feature | CD47 Pathway | Sialylated CD43 Pathway |
|---|---|---|
| Mechanism | Protein-Protein Interaction | Sialic Acid-Siglec Interaction |
| Receptor | SIRPα | Siglec family (e.g., Siglec-7/9) |
| Signal Type | “Don’t eat me” | Inhibitory sugar-based signal |
| Clinical Status | Extensively studied/Trials | Emerging target |
Why Sialylation Matters
The “sialylated” part of CD43 is the key. Sialic acids are nine-carbon sugars that often cap the ends of glycan chains on the cell surface. In many cancers, the overexpression of these sugars creates a “sialic acid shield” that protects the tumor from the immune system. This is a broader phenomenon seen across various malignancies, but its specific interaction with CD43 in AML creates a particularly effective barrier.
When researchers strip away these sialic acids or block the receptors that recognize them, the macrophages regain their ability to attack the leukemia cells. This suggests that the most effective approach may not be to target the CD43 protein itself, but rather the specific chemical modifications (the sialylation) that build the protein inhibitory. This nuance is critical for developing drugs that are precise enough to avoid harming healthy immune cells while aggressively targeting the cancer.
According to the Leukemia & Lymphoma Society, the complexity of AML’s genetic and molecular profile is why “one-size-fits-all” treatments often fail. The emergence of CD43 as a target aligns with the broader move toward personalized medicine and combination immunotherapy.
The Path Toward New Therapies
The identification of CD43 as a critical immune checkpoint opens several doors for drug development. One potential avenue is the use of antibodies that specifically target the sialylated form of CD43, or the use of enzymes called sialidases that can “strip” the sugar shield from the cancer cells before they are targeted by other drugs.
Another promising direction is the development of bispecific antibodies—molecules designed to bind to two different targets simultaneously. A bispecific antibody could potentially bind to both CD47 and CD43 on the AML cell, while simultaneously anchoring to a receptor on the macrophage. This would not only remove the “don’t eat me” signals but actively pull the macrophage toward the cancer cell, forcing phagocytosis.
However, challenges remain. The immune system is finely balanced, and blocking inhibitory signals can sometimes lead to “off-target” effects, such as the destruction of healthy platelets or red blood cells, which also express certain inhibitory markers. The goal for the next generation of AML therapies is to achieve “selective clearance,” ensuring that only the malignant blasts are destroyed.
Current Constraints and Unknowns
- Patient Variability: It is not yet fully known what percentage of AML patients rely primarily on CD43 versus CD47 for immune evasion.
- Toxicity Profiles: The safety of blocking Siglec receptors on a systemic level requires further study in human clinical trials.
- Combination Timing: Determining whether CD43 blockade should precede or accompany CD47 inhibition is a key area of ongoing research.
For those tracking the progress of AML research, the ClinicalTrials.gov database remains the primary resource for identifying upcoming studies involving macrophage-targeting agents and novel checkpoint inhibitors.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their healthcare provider regarding treatment options for acute myeloid leukemia.
The next phase of this research will likely involve preclinical models testing the synergy of dual CD47/CD43 inhibition to determine if it significantly increases the rate of leukemia cell clearance compared to monotherapies. These findings will be essential for designing the first human trials targeting this specific pathway.
We invite readers to share this update with the patient community and welcome your thoughts in the comments section below.
